当前位置: X-MOL 学术Assay Drug Dev. Technol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of a QPatch-Automated Electrophysiology Assay for Identifying TMEM16A Small-Molecule Inhibitors.
ASSAY and Drug Development Technologies ( IF 1.6 ) Pub Date : 2020-04-01 , DOI: 10.1089/adt.2019.962
Kathryn A Henckels 1 , David Fong 2 , Jonathan E Phillips 2
Affiliation  

The calcium-activated chloride channel, TMEM16A, is involved in airway hydration and bronchoconstriction and is a promising target for respiratory disease. Drug development efforts around channels require an electrophysiology-based assay for identifying inhibitors or activators. TMEM16A has proven to be a difficult channel to record on automated electrophysiology platforms due to its propensity for rundown. We developed an automated, whole-cell, electrophysiology assay on the QPatch-48 to evaluate small-molecule inhibitors of TMEM16A. In this assay, currents remained stable for a duration of roughly 11 min, allowing for the cumulative addition of five concentrations of compounds and resulted in reproducible IC50s. The absence of rundown was likely due to a low internal free-calcium level of 250 nM, which was high enough to produce large currents, but also maintained the voltage dependence of the channel. Current amplitude averaged 6 nA using the single-hole QPlate and the channel maintained outward rectification throughout the recording. Known TMEM16A inhibitors were tested and their IC50s aligned with those reported in the literature using manual patch-clamp. Once established, this assay was used to validate novel TMEM16A inhibitors that were identified in our high-throughput fluorescent-based assay, as well as to assist in structure-activity relationship efforts by the chemists. Overall, we demonstrate an easy to operate, reproducible, automated electrophysiology assay using the QPatch-48 for TMEM16A drug development efforts.

中文翻译:

QPatch自动电生理测定方法的开发,用于鉴定TMEM16A小分子抑制剂。

钙激活的氯离子通道TMEM16A参与气道水合和支气管收缩,是呼吸系统疾病的有希望的靶标。围绕通道的药物开发工作需要基于电生理的分析方法来鉴定抑制剂或激活剂。由于TMEM16A易于耗尽,因此已被证明是很难在自动电生理平台上进行记录的渠道。我们在QPatch-48上开发了自动化的全细胞电生理测定法,以评估TMEM16A的小分子抑制剂。在此分析中,电流在大约11分钟的时间内保持稳定,从而允许累积添加五种浓度的化合物,并产生可再现的IC50。没有内部损耗的原因可能是内部游离钙水平低至250 nM,足以产生大电流,而且还保持了通道的电压依赖性。使用单孔QPlate平均电流幅度为6 nA,并且在整个记录过程中通道保持向外整流。测试了已知的TMEM16A抑制剂,并使用手动膜片钳将其IC50与文献中报道的那些进行了比对。一旦建立,该测定将用于验证在我们的基于高通量荧光的测定中鉴定出的新型TMEM16A抑制剂,以及协助化学家进行构效关系研究。总体而言,我们证明了使用QPatch-48进行TMEM16A药物开发的一种易于操作,可重现的自动化电生理测定方法。使用单孔QPlate平均电流幅度为6 nA,并且在整个记录过程中通道保持向外整流。测试了已知的TMEM16A抑制剂,并使用手动膜片钳将其IC50与文献中报道的那些进行了比对。一旦建立,该测定将用于验证在我们的基于高通量荧光的测定中鉴定出的新型TMEM16A抑制剂,以及协助化学家进行构效关系研究。总体而言,我们展示了使用QPatch-48进行TMEM16A药物开发的一种易于操作,可重现的自动化电生理测定方法。使用单孔QPlate平均电流幅度为6 nA,并且在整个记录过程中通道保持向外整流。测试了已知的TMEM16A抑制剂,并使用手动膜片钳将其IC50与文献中报道的那些进行了比对。一旦建立,该测定将用于验证在我们的基于高通量荧光的测定中鉴定出的新型TMEM16A抑制剂,以及协助化学家进行构效关系研究。总体而言,我们证明了使用QPatch-48进行TMEM16A药物开发的一种易于操作,可重现的自动化电生理测定方法。该测定法用于验证在我们的高通量荧光基测定法中鉴定出的新型TMEM16A抑制剂,以及协助化学家进行构效关系研究。总体而言,我们证明了使用QPatch-48进行TMEM16A药物开发的一种易于操作,可重现的自动化电生理测定方法。该测定法用于验证在我们的高通量荧光基测定法中鉴定出的新型TMEM16A抑制剂,以及协助化学家进行构效关系研究。总体而言,我们证明了使用QPatch-48进行TMEM16A药物开发的一种易于操作,可重现的自动化电生理测定方法。
更新日期:2020-04-01
down
wechat
bug